Corcept Therapeutics' focus on cortisol-modulating drugs and its strong financials make it a promising investment. The company's near-monopolistic position in a niche market and the potential market expansion with Relacorilant, targeting diabetes and ovarian cancer, are significant growth drivers. Despite legal risks and reliance on a single product, the innovative pipeline could diversify revenue streams and drive future growth.